Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

COL1A1 as biomarker of Type 2 diabetes, and application of COL1A1

A type 2 diabetes, biomarker technology, applied in the field of biomedicine, can solve problems that have not yet been reported, and achieve the effect of improving the expression level

Active Publication Date: 2021-03-26
FUJIAN AGRI & FORESTRY UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above patent is the discovery and application of Col1a1 and liver-related diseases, which is different from the content of the invention. At the same time, there have been no reports on the relationship between Col1a1 and intestinal tract and type 2 diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • COL1A1 as biomarker of Type 2 diabetes, and application of COL1A1
  • COL1A1 as biomarker of Type 2 diabetes, and application of COL1A1
  • COL1A1 as biomarker of Type 2 diabetes, and application of COL1A1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: Differential expression of Col1a1 found in model group rats and normal rats under proteomics and bioinformatics analysis

[0029] In the present invention, all 6810 proteins are detected through TMT proteomics analysis, combined with bioinformatics analysis means, and a P value lower than 0.05 is set as a threshold to judge significant differences. Among them, in the comparison between the model group and the normal group, 265 proteins showed differential expression. Furthermore, through the differential protein network interaction diagram, it was found that Col1a1 is in the core position with a large number of functional network nodes in the protein interaction network, indicating that this protein may play an extremely important role in type 2 diabetes and may be involved in The process of maintaining normal glucose metabolism function ( figure 1).

Embodiment 2

[0030] Example 2: Differential expression of proteins and genes

[0031] The present invention specifically verified the expression changes of Col1a1, PI3K, MEK and ERK1 / 2 proteins and genes in the jejunum by qPCR and Western blot methods, and found that the model group had significantly lower expression than the normal group, and was responsible for the conservative targeted regulation of Col1a1 miRNA (let-7g-5p) was overexpressed, and then Col1a1 was significantly upregulated in the comparison between the administration group and the model group. At the same time, PI3K, MEK and ERK1 / 2 were also significantly up-regulated, while the miRNA (let-7g-5p) responsible for the conservative target regulation of Col1a1 was significantly reduced, which shows that Col1a1 does play a key role in type 2 diabetes ( figure 2 ). The nucleotide sequence and amino acid sequence of Col1a1 are shown in SEQ ID NO.1-2 respectively, the nucleotide sequence and amino acid sequence of PI3K are sho...

Embodiment 3

[0050] Example 3: Changes in blood sugar levels, insulin and glycosylated hemoglobin between the model group and the administration group after the administration of Enteromorpha oligosaccharides

[0051] The present invention specifically verified the effect of Col1a1 down-regulation on the fasting insulin and glycosylated hemoglobin of the model group and the administration group, and found that the fasting insulin and glycosylated hemoglobin levels in the model group were significantly down-regulated and Up-regulation, and after restoring the expression of Col1a1, the two returned to normal levels, indicating that the inhibition of Col1a1 deteriorated the body's ability to regulate glucose metabolism (Figure 3). The specific steps are as follows: 1. Fasting blood glucose measurement: through Enteromorpha The oligosaccharides were intervened for two weeks to detect the fasting blood glucose (FBG) level through the OMRON blood glucose meter; 2. Collect the blood of the rats, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of novel Col1a1 protein as a biomarker for identifying Type 2 diabetes. An experiment discovers that the expression quantity of the Col1a1 protein in the jejunum of a Type 2 diabetes rat group is obviously smaller than the expression quantity of enteromorpha oligosaccharide and the expression quantity in the jejunum of a normal rat group. A tandem mass tag (TMT) based on liquid mass spectrometry indicates that Col1a1 serves as a protein receptor which makes a greatest effect in an ECM pathway. Further through fluorescent quantitation and protein immunoblotting, transcription and protein level change of the Col1a1 protein can be verified so as to prove that the Col1a1 protein will be a new therapeutic target and biomarker for the Type 2 diabetes.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a biomarker related to diabetes and its application, specifically the biomarker is Col1a1. Background technique [0002] Type 2 diabetes (Type 2 diabetes), as a heterogeneous, hormonal and metabolic disease, is characterized by hyperglycemia and insulin resistance, and is currently spreading in the population with a very high incidence. According to statistics released by the International Diabetes Federation, about 451 million people worldwide will be diagnosed with diabetes in 2019, and by 2045, this number will reach a staggering 702 million people. With the rapid development of medical and health technology in recent decades, as well as the continuous improvement of various drug treatment and testing methods, gratifying progress has been made in the treatment of diabetes. Nevertheless, diabetes and its complications still threaten people's health. [0003] In addition to inducing ob...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68A61K31/702A61K31/715A61P3/10C08B37/00
CPCC12Q1/6883G01N33/6893A61K31/702A61K31/715A61P3/10C08B37/0003C12Q2600/158G01N2333/78G01N2800/042
Inventor 赵超陈逸晗林国鹏
Owner FUJIAN AGRI & FORESTRY UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com